IFN beta-1a - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.74 [0.51, 5.93]< 10%1 study (1/-)18.9 %some concernnot evaluable moderatecrucial-
deaths 1.17 [0.97, 1.41]< 10%2 studies (2/-)4.6 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.74 [0.51, 5.93]< 10%1 study (1/-)18.9 %some concernnot evaluable moderatecrucial-
clinical improvement 0.99 [0.87, 1.13]> 10%1 study (1/-)44.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.01 [0.79, 1.29]> 10%1 study (1/-)53.2 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 0.99 [0.87, 1.13]> 10%1 study (1/-)44.0 %some concernnot evaluable moderateimportant-
death or ventilation 1.05 [0.90, 1.23]< 10%1 study (1/-)27.2 %some concernnot evaluable moderateimportant-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.